News Release 

Optimizing immunization with Sanaria® PfSPZ-CVac malaria vaccine

Sanaria Inc.

Research News

ROCKVILLE, MD, USA - June 8, 2021 - The PfSPZ malaria vaccines of Sanaria Inc. are unique in vaccine development as they are composed of weakened (attenuated) forms of the live parasite cells that cause malaria. These parasite cells are called eukaryotic cells and there are no vaccines against any infectious disease composed of such cells. Furthermore, there are no licensed vaccines against any infectious disease caused by a eukaryotic pathogen. Thus, Sanaria and its collaborators have had to take a step by step empirical approach to optimizing immunization with PfSPZ vaccines to achieve a safe, effective, durable, and broadly protective malaria vaccine.

Two recent landmark malaria vaccine studies have moved the optimization process forward and highlighted the strong protective efficacy of Sanaria® PfSPZ-CVac in malaria-naïve adults. In a study published in Nature Communications, 77% (10/13) of subjects vaccinated with a 3-dose regimen administered within a 4 week period were protected 12 weeks later when challenged with live malaria parasites of a strain genetically quite distant (heterologous) from the vaccine strain.

"This high-level efficacy of 3 months would be excellent for protecting travelers to malaria endemic regions against the disease," said Professor Peter Kremsner, Director of the Institute of Tropical Medicine, Travel Medicine and Human Parasitology at the University of Tübingen, Germany who led the study. "We have demonstrated excellent efficacy with just three co-administrations of PfSPZ-CVac and chloroquine, paving the way for a product that can be used for travelers worldwide."

The second study, published in PLoS Pathogen, revealed the profound negative effects of the presence of blood stage malaria parasites on vaccine efficacy. Vaccinations given 7 days apart conferred no protection in study subjects, and this timing coincided with the emergence of parasites into the blood from the liver after previous doses. By changing the timing between doses to 5 days, a regimen first reported in Nature by the Tübingen team, PfSPZ-CVac protective efficacy dramatically increased to 75%. "This study demonstrates the capacity of the malaria parasite to manipulate immune responses of the human host in favor of its own survival and demonstrates how we can optimize the spacing of doses of PfSPZ-CVac to overcome this negative impact," said Dr. Sean Murphy, first author of the paper and Associate Professor at the Department of Laboratory Medicine and Pathology, University of Washington. "Given the high prevalence of malaria infection, these results also have profound implications for malaria vaccine immunization strategies in Africa."

Sanaria® PfSPZ-CVac is a chemo-attenuated, live whole parasite vaccine in which an anti-malarial drug is co-administered with the parasite cells (PfSPZ), to kill parasites. Efficacy in these studies was measured by controlled human malaria infection (CHMI) in which well-characterized, infectious malaria parasites were administered to vaccinated subjects. This is a highly rigorous measure of efficacy because a 100% infective dose of disease-causing parasites is administered and the heterologous challenge strain used in Tübingen is genetically more distant from the vaccine strain than parasites encountered naturally in Africa. Additionally, CHMI is not subject to seasonal variations, subject behaviors, or other unknown variables, as is the case in observational field trials.


These studies were sponsored by Sanaria Inc. with support from the German Center for Infection Research (DZIF) at University Hospital, Tübingen, Germany, as well as support from the National Institute of Allergy and Infectious Diseases, NIH, at the Vaccine and Treatment Evaluation Unit at the Kaiser Permanente Washington Health Research Institute.

About Sanaria Inc.: Sanaria is a biotechnology company based in Rockville, Maryland (USA) whose mission is development of whole parasite PfSPZ vaccines to protect against malaria. Sanaria's vaccines have been highly protective against malaria in clinical trials in the US, Africa, and Europe. Sanaria's vaccines will be used to prevent malaria in individuals and in combination with other malaria control measures to stop malaria transmission and eliminate malaria in defined geographic regions.

About the DZIF: The German Center for Infection Research coordinates translational infection research in Germany and provides strategic direction. Its mission is to translate results from basic infectious disease research into clinical research and bring them to patients. Thirty five DZIF research institutions work together against the global threat of infectious diseases. The Tübingen site coordinates research on malaria under the guidance of the Director and site spokesperson Prof. Peter Kremsner.

About the Department of Laboratory Medicine and Pathology, University of Washington: The Department of Laboratory Medicine and Pathology provides biomedical clinical care, education, and research and is internationally recognized as a center for clinical and basic science research. Dr. Sean Murphy serves in the Department's Division of Microbiology and his research program is focused on malaria vaccine development, diagnostics, and clinical trials.

About the Kaiser Permanente Washington Health Research Institute: The Kaiser Permanente Washington Health Research Institute brings together a faculty of investigators, research associates, and biostatisticians with broad expertise in medicine, biostatistics, and other relevant disciplines. Over the past five years, Dr. Lisa Jackson and the Institute have joined forces with other Seattle area institutions to perform several CHMI studies to accelerate malaria vaccine developmen

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.